Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MIRA

Mira Pharmaceuticals Inc

Dec 08 • 04:00PM ET

1.58

Dollar change -0.23
Percentage change -12.71	%

Healthcare • Drug Manufacturers - General • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	47.10%	Shs Outstand	14.75M	Perf Week	-58.42%
Market Cap	23.35M	Forward P/E	-	EPS next Y	-	Insider Trans	4.13%	Shs Float	7.82M	Perf Month	0.10%
Income	-	PEG	-	EPS next Q	-0.23	Inst Own	0.01%	Short Float / Ratio	0.04% / 0.01	Perf Quarter	-73.45%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.00M	Perf Half Y	-
Book/sh	0.55	P/B	2.88	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	0.40	P/C	3.98	EPS next 5Y	-	ROE	-	52W Range	1.33 - 7.98	Perf YTD	-78.71%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-80.20%	Beta	-
Dividend %	-	Quick Ratio	6.99	Sales past 5Y	0.00%	Gross Margin	-	52W Low	18.80%	ATR	0.67
Employees	-	Current Ratio	6.99	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.04	Volatility	25.07% 28.50%
Optionable	No	Debt/Eq	0.01	EPS Q/Q	-48.08%	Profit Margin	-	Rel Volume	1.10	Prev Close	1.81
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	202.21K	Price	1.58
Recom	-	SMA20	-47.25%	SMA50	-47.63%	SMA200	-62.56%	Volume	223,177	Change	-12.71%

Dec-04-23 08:00AM	MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations (PR Newswire) -5.26%
Nov-29-23 08:00AM	MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% (PR Newswire)
Nov-21-23 10:42AM	MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time (PR Newswire) -16.13%
10:09AM	MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a (PR Newswire)
Nov-20-23 08:00AM	MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 (PR Newswire) +40.06%
07:23AM	Loading…
Oct-26-23 07:23AM	MIRA: Developing Cannabis with Benefits and Without Side Effects (Zacks) +5.38%
Sep-18-23 08:30AM	MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot (PR Newswire) +38.80%
Sep-05-23 08:31AM	MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts (PR Newswire)
Aug-31-23 08:31AM	MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit (PR Newswire)
Aug-29-23 11:39AM	MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time (PR Newswire)
Aug-09-23 09:35AM	MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast (ACCESSWIRE)
Aug-03-23 02:40PM	MIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THC (News Direct)

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company engages in developing its product candidate, MIRA1a, as a synthetic cannabinoid analog for treating anxiety & chronic pain by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors. MIRA Pharmaceuticals was founded by Adam Kaplin on September 3, 2020 and is headquartered in Baltimore, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cappy George	10% Owner	Aug 07	Buy	7.00	119,048	833,336	2,859,318	Aug 24 05:38 PM
Cappy George	10% Owner	Aug 02	Buy	7.00	157,170	1,100,190	2,740,270	Aug 04 01:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MIRA

Mira Pharmaceuticals Inc

Upgrade your FINVIZ experience